Garrido C - Search Results

1

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.

Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V, de Mendoza C; SINRES Group. Garrido C, et al. Antimicrob Agents Chemother. 2012 Jun;56(6):2873-8. doi: 10.1128/AAC.06170-11. Epub 2012 Mar 26. Antimicrob Agents Chemother. 2012. PMID: 22450969 Free PMC article.

2

Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.

de Mendoza C, Garrido C, Corral A, Zahonero N, Soriano V. de Mendoza C, et al. Among authors: garrido c. AIDS. 2008 Jan 11;22(2):311-3. doi: 10.1097/QAD.0b013e3282f4244f. AIDS. 2008. PMID: 18097236

3

Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola.

Garrido C, Zahonero N, Fernándes D, Serrano D, Silva AR, Ferraria N, Antúnes F, González-Lahoz J, Soriano V, de Mendoza C. Garrido C, et al. J Antimicrob Chemother. 2008 Mar;61(3):694-8. doi: 10.1093/jac/dkm515. Epub 2008 Jan 24. J Antimicrob Chemother. 2008. PMID: 18218644

4

[Resistance to integrase inhibitors].

Garrido C, de Mendoza C, Soriano V. Garrido C, et al. Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:40-6. doi: 10.1016/s0213-005x(08)76572-8. Enferm Infecc Microbiol Clin. 2008. PMID: 19572425 Review. Spanish.

5

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.

Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C. Garrido C, et al. J Antimicrob Chemother. 2010 Feb;65(2):320-6. doi: 10.1093/jac/dkp423. Epub 2009 Dec 9. J Antimicrob Chemother. 2010. PMID: 20007331

6

New therapeutic strategies for raltegravir.

Garrido C, Soriano V, de Mendoza C. Garrido C, et al. J Antimicrob Chemother. 2010 Feb;65(2):218-23. doi: 10.1093/jac/dkp447. Epub 2009 Dec 16. J Antimicrob Chemother. 2010. PMID: 20016017 Review.

7

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I, de Mendoza C. Garrido C, et al. Antiviral Res. 2011 Jun;90(3):164-7. doi: 10.1016/j.antiviral.2011.03.178. Epub 2011 Mar 23. Antiviral Res. 2011. PMID: 21439330

8

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

Garrido C, de Mendoza C, Alvarez E, García F, Morello J, Garcia S, Ribera E, Rodríguez-Novoa S, Gutierrez F, Soriano V; Sinres Team. Garrido C, et al. AIDS Res Hum Retroviruses. 2012 Feb;28(2):156-64. doi: 10.1089/AID.2010.0370. Epub 2011 May 6. AIDS Res Hum Retroviruses. 2012. PMID: 21457126

9

Antiviral effect of raltegravir on HTLV-1 carriers.

Treviño A, Parra P, Bar-Magen T, Garrido C, de Mendoza C, Soriano V. Treviño A, et al. Among authors: garrido c. J Antimicrob Chemother. 2012 Jan;67(1):218-21. doi: 10.1093/jac/dkr404. Epub 2011 Sep 29. J Antimicrob Chemother. 2012. PMID: 21965433

10

Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.

Garrido C, Rallón N, Soriano V, Lopez M, Zahonero N, de Mendoza C, Benito JM. Garrido C, et al. AIDS. 2012 Mar 13;26(5):551-7. doi: 10.1097/QAD.0b013e3283509826. AIDS. 2012. PMID: 22210634

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

553 results

Search Page

Filters